GlycoMimetics, Inc.

About GlycoMimetics, Inc.

GlycoMimetics is an oncology-focused biotechnology company. We are dedicated to improving the lives of patients by discovering, developing and commercializing novel, small-molecule glycomimetic product candidates.

Our management team consists of industry leaders with deep experience in the pharmaceutical/biotech industry.

Since our inception, we have developed a diversified product pipeline. Today, the company’s proprietary investigational drug for acute myeloid leukemia (AML) is being evaluated in two pivotal Phase 3 clinical trials.